Capitol Correspondence - 04.22.19

FYI: FDA wants Feedback on Cannibas-Based Therapies to Review

Share this page

The Farm Bill passed in late 2018 removed hemp as a controlled substance and instead classified it as an agricultural product. Following this change, then Commissioner Gottlieb of the Food and Drug Administration (FDA) announced that change did not automatically permit use of non hallucinogen, cannabis-based products but that FDA would conduct their standard reviews of products as they moved forward.  For those interested, there will be a public hearing on May 31 held by the FDA to begin discussions of what should be reviewed and considerations that the agency should have.